SEC Form 3 · accession 0001209191-16-133339
Audentes Therapeutics, Inc. · BOLD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas J. Schuetz
Director
Period of report
Jul 19, 2016
Accepted (ET)
Jul 19, 2016 · 5:18 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001628738
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 89,695 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $0.79 | holding | — | — | — | — | Sep 25, 2023 | Common Stock | 18,086 | — | D |
| Stock Option (right to buy)F2 | $2.19 | holding | — | — | — | — | May 27, 2025 | Common Stock | 5,605 | — | D |
Explanation of responses
- F1The option vested as to 25% of the total shares on January 1, 2014, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on January 1, 2017, subject to the reporting person's provision of service to the issuer on each vesting date and to accelerated vesting upon a change of control of the issuer.
- F2The option vests as to 8.333% of the total shares quarterly, beginning August 27, 2015, with 100% of the total shares vested and exercisable on May 27, 2018, subject to the reporting person's provision of service to the issuer on each vesting date and to accelerated vesting upon a change of control of the issuer.